<DOC>
	<DOCNO>NCT00304629</DOCNO>
	<brief_summary>The long-term safety efficacy galantamine ( 12 mg bid ) document one year open-label treatment subject Alzheimer 's Disease complete GAL-INT-8 trial ( 400 eligible patient ) . Safety track mean adverse event report , laboratory parameter physical exam . Long-term efficacy evaluate mean Alzheimer 's Disease Assessment Scale ( ADAS ) activity daily live scale Disability Assessment Dementia Scale ( DAD )</brief_summary>
	<brief_title>Long-term Safety Efficacy Galantamine Alzheimer 's Disease</brief_title>
	<detailed_description>This twelve-month , open-label trial treatment 12 mg bid galantamine evaluate . Only subject take trial medication 24-month trial period GAL-INT-8 eligible . Safety assess periodic physical examination , vital sign , ECG laboratory test report adverse event . The ADAS-cognitive scale DAD scale use document long-term efficacy . Patients see 6 monthly interval ADAS-cognitive scale DAD scale perform end trial . The treatment consist tablet contain 12 mg galantamine . Duration treatment equal 12 month . Patients receive 1 tablet twice daily preferably take food ( breakfast morning approximately 8 AM snack meal even approximately 6PM ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Patients must take trial medication 24month trial period GALINT8 enrol within 1 month completion Patients primary caregiver give informed consent participation trial Patients must remain good health , determine medical history , complete physical examination laboratory test If patient develop , trial GALINT8 , symptoms neurological psychiatric disease might contribute dementia , subject enrol . This include subject develop neurodegenerative disorder Parkinson 's disease , Pick 's disease Huntington 's chorea , CreutzfeldtJacob disease , subject cognitive impairment result stroke , acute cerebral trauma , hypoxic cerebral damage , infection primary metastatic cerebral neoplasia Subjects follow coexist medical condition : ) Any history epilepsy convulsion except febrile convulsion childhood b ) Peptic ulcer : ulcer consider still `` active '' , i.e. , treatment condition start &lt; 3 month ago treatment successful ( symptom still present ) , subject eligible . c ) Clinically significant hepatic , renal , pulmonary , metabolic endocrine disturbance Patients current , clinically significant cardiovascular disease would expect limit subject 's ability complete 12month trial . The follow would usually consider clinically significant cardiovascular disease : ) Unstable angina angina coronary artery disease require change medication ( antiangina digitalis ) within last 3 month b ) Decompensated congestive heart failure i.e . symptom occur subject stable medication rest light exercise ( NYHA III IV ) . Note : sign decompensation pretibial malleolar oedema exercise tolerance still reasonable ( absence dyspnoea ) subject exclude c ) Cardiac disease potentially result syncope , near syncope alteration mental status In addition , follow condition lead exclusion : atrial fibrillation without prophylactic treatment prevent thromboembolic stroke , bradycardia &lt; 50 beats/min. , atrioventricular block &gt; first degree . ) Severe mitral aortic valvular disease e ) Hypotension treatment hypotension f ) Systolic blood pressure great 170 mmHg diastolic blood pressure great 110 mmHg Patients use agent treatment dementia ( approve , experimental , include counter agent ) , include , limited nootropic agent , cholinomimetic agent , choline , oestrogens take without medical need , chronic NSAIDs ( 30 consecutive day ) , vitamin E 30 IU daily , deprenyl Conditions could interfere absorption compound evaluation disease</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>cholinesterase inhibitor</keyword>
	<keyword>galantamine</keyword>
</DOC>